| name | es-cpp-treatment-approach |
| description | This skill determines the appropriate indications and treatment regimens for central precocious puberty in childhood cancer survivors, recommending to follow the same approaches (e.g., GnRHa therapy) used in the noncancer population. Triggers include: "How should I treat central precocious puberty in this survivor?" or "What GnRHa regimen is suitable for CPP in childhood cancer?" |
Select CPP treatment strategy
STEP 1 — Gather Information
Collect history of hydrocephalus, tumors near hypothalamus/pituitary, hypothalamic–pituitary radiation exposure, and prior gonadotoxic therapy. Assess clinical pubertal signs (breast development in females, testicular volume not sole indicator in males). Obtain serum testosterone and LH levels before 10:00 AM, and consider Tanner staging, estradiol, and uterine length by ultrasound if needed.
STEP 2 — Rule In / Rule Out
If clinical evidence of pubertal onset before age 8 in girls or 9 in boys is present with elevated LH/FSH or sex steroids consistent with central activation, rule in CPP; otherwise rule out CPP.
STEP 3 — Classify or Stratify
Classify CPP patients as those with concomitant growth hormone deficiency (GHD) versus those without GHD, as this influences whether combined GnRHa and GH therapy is indicated.
STEP 4 — Decide
For confirmed CPP, initiate GnRHa therapy (e.g., leuprolide 11.25 mg IM monthly or equivalent) following noncancer protocols; if GHD is also present, add GH treatment per guideline; monitor LH suppression, Tanner progression, and height velocity every 3–6 months.
Clinical Guardrails / Mimics / Pitfalls
Do not rely on testicular volume alone to assess puberty in males with gonadotoxic therapy; avoid missing CPP due to gonadotropin elevation from primary gonadal injury; do not delay treatment based solely on age <8 years without confirming central activation; watch for pseudotumor cerebri or scoliosis exacerbation during GnRHa therapy.
Concrete Clinical Example
A 7‑year‑old female survivor of craniopharyngioma treated with surgery and 18 Gy cranial radiation presents with Tanner stage 2 breast development, LH 5 IU/L, estradiol 20 pg/mL, and normal GH testing. CPP is ruled in, GHD absent. Start leuprolide 11.25 mg IM monthly; after 6 months LH <0.2 IU/L and breast Tanner stage unchanged, continue therapy until appropriate age for spontaneous puberty.
Source: Hypothalamic Pituitary and Growth Disorders in Survivors of Childhood Cancer: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2018, 10.1210/jc.2018-01175
